Amneal Reports Second Quarter 2026 Financial Results

Rhea-AI Summary

Amneal Pharmaceuticals (Nasdaq: AMRX) reported Q2 2026 net revenue of $796 million, up 10% year over year, with GAAP net income of $58 million and diluted EPS of $0.18. Adjusted EBITDA was $206 million and adjusted diluted EPS was $0.30, up 12% and 20%, respectively.

Specialty net revenue grew 17%, Affordable Medicines grew 13%, while AvKARE declined 4%. In July, Amneal repriced its $2.084 billion Term Loan B, cutting the margin by 50 bps and targeting about $12 million in annual interest savings, and plans an additional $350 million Term Loan B to help fund the pending Kashiv Biosciences acquisition.

The company raised 2026 guidance: net revenue to $3.10–$3.20 billion, adjusted EBITDA to $750–$780 million, and adjusted diluted EPS to $0.96–$1.06. Capital expenditure guidance increased to about $150 million from about $110 million.

Positive

• Q2 2026 net revenue $796M, up 10% year over year
• Q2 GAAP net income $58M, up 157% vs. Q2 2025
• Q2 adjusted EBITDA $206M, up 12% vs. prior year quarter
• Q2 adjusted diluted EPS $0.30, up 20% from $0.25
• 2026 guidance raised for revenue, adjusted EBITDA and adjusted EPS
• Term Loan B repricing on $2.084B expected to save ~$12M annually

Negative

• AvKARE net revenue down 4% year over year in Q2 2026
• Operating cash flow for six months 2026 was -$48M vs. +$91M in 2025
• Capital expenditure guidance raised to ~$150M from ~$110M for 2026
• Cash and equivalents fell to $127.6M from $282.0M since year-end 2025
• Net cash used in investing -$144M for six months 2026 vs. -$44M in 2025

News Explained

The repricing remains pending until as early as August 3, while Kashiv financing would add a planned $350 million loan at acquisition closing.

Amneal’s Term Loan B repricing has been launched but is not yet stated as closed; if completed, it would reduce the rate on $2.084 billion of debt, while the pending Kashiv purchase is planned to use an additional $350 million Term Loan B at acquisition closing.

A repricing changes the interest rate on existing debt; the separate Term Loan B is described as intended financing that would be incurred at the Kashiv acquisition closing.

Although the headline calls the repricing successful, the company says it was launched in July and expects it to close as early as August 3, 2026, so the lower rate is not yet disclosed as closed.

The June 30, 2026 balance sheet reported $127,637 of cash and cash equivalents, while the six-month cash-flow statement reported $47,987 of cash used in operating activities.

The stated milestones are the repricing’s earliest August 3, 2026 closing and the Kashiv acquisition closing, when the additional loan is expected to be incurred.

Market Context

The stock is down -7.5% following this news. Q1 2026 earnings produced a -3.79% 24-hour reaction in ...

Analysis

The stock is down -7.5% following this news. Q1 2026 earnings produced a -3.79% 24-hour reaction in the historical record. This release again combined raised guidance with debt repricing; the comparison highlights earnings-response divergence, while Net Selling insider activity was a sourced risk.

Key Figures

Q2 net revenue: $796 million GAAP net income: $58 million Adjusted EBITDA: $206 million +5 more

8 metrics

Q2 net revenue $796 million Q2 2026; up 10% year over year

GAAP net income $58 million Q2 2026; compared with $22 million in Q2 2025

Adjusted EBITDA $206 million Q2 2026; up 12% year over year

Diluted EPS $0.18 Q2 2026; compared with $0.07 in Q2 2025

Interest-rate reduction 50 basis points Term Loan B repricing from SOFR plus 300 basis points to SOFR plus 250 basis points

Annual cash interest savings about $12 million Expected from the July 2026 debt repricing

2026 revenue guidance $3.10 billion–$3.20 billion Updated guidance; prior guidance was $3.05 billion–$3.15 billion

2026 adjusted EBITDA guidance $750 million–$780 million Updated guidance; prior guidance was $740 million–$770 million

Previous Earnings Reports

5 past events · Latest: May 07 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
May 07	Q1 earnings	Positive	-3.8%	Revenue, profit, and adjusted EBITDA increased while 2026 guidance remained raised.
Feb 27	Q4 earnings	Positive	-4.7%	Full-year results and 2026 guidance included revenue and adjusted EPS growth.
Oct 30	Q3 earnings	Positive	-4.1%	Revenue increased and 2025 guidance was updated alongside branded product launches.
Aug 05	Q2 earnings	Positive	+2.1%	Revenue, adjusted EBITDA, and adjusted EPS increased with guidance raised.
Jul 21	Preliminary earnings	Positive	-0.8%	Preliminary revenue and adjusted EBITDA increased with improved leverage metrics.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

The supplied earnings history showed predominantly negative 24-hour reactions despite positive operating updates; its average move was -2.24%.

Key Terms

gaap, adjusted ebitda, sofr, term loan b, +1 more

5 terms

gaap financial

"GAAP Net Income of $58 million"

GAAP, or Generally Accepted Accounting Principles, are a set of standardized rules and guidelines that companies follow when preparing their financial statements. They ensure consistency, transparency, and comparability across different companies, making it easier for investors to understand and compare financial information accurately. This helps investors make informed decisions based on trustworthy and uniform financial reports.

View in glossary

adjusted ebitda financial

"Adjusted EBITDA of $206 million"

Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.

sofr financial

"Secured Overnight Financing Rate (“SOFR”)"

The Secured Overnight Financing Rate (SOFR) is a market benchmark that measures the cost of borrowing cash overnight using U.S. Treasury securities as collateral. Investors watch SOFR because it acts like a speedometer for short-term interest costs—affecting loan rates, bond yields and the pricing of interest-rate contracts—so movements change borrowing expenses, cash returns and the value of interest-sensitive investments.

term loan b financial

"the Company launched a repricing of its $2.084B Term Loan B"

A Term Loan B (TLB) is a large, syndicated loan made to a company that is typically sold to institutional investors rather than held by banks; think of it as a long-term mortgage from a group of investors with higher interest and smaller early payments. It matters to investors because it changes a company’s debt cost, repayment schedule and credit risk—factors that affect profit, cash flow and the market value of both the company’s equity and its traded debt.

non-gaap financial

"The Company presents GAAP and adjusted (non-GAAP) quarterly results."

Non-GAAP refers to financial measures that companies use to show their earnings or performance without including certain expenses or income that are often added back to give a different picture. It matters because it can make a company's results look better or more favorable, but it may also hide important costs, so investors need to look at both GAAP (official rules) and non-GAAP numbers to get a full understanding.

View in glossary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

– Q2 2026 Net Revenue of $796 million; GAAP Net Income of $58 million; Diluted Income per Share of $0.18 –
– Adjusted EBITDA of $206 million; Adjusted Diluted EPS of $0.30 –
– Raising 2026 Full Year Guidance –
– Successful Debt Repricing in July Reduces Interest Cost –

BRIDGEWATER, N.J., July 30, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced its results for the second quarter ended June 30, 2026.

“Amneal delivered strong, broad-based performance in the second quarter and first half of 2026, reflecting the strength of our diversified portfolio and the contributions from multiple growth drivers. This robust first-half performance gives us confidence to raise our full-year 2026 guidance for the second time this year. We are excited about the pending Kashiv transaction, which will establish biosimilars as an important new, durable growth vertical for Amneal, further diversifying our portfolio and expanding our long-term growth opportunities. As we look ahead to the remainder of 2026, 2027 and beyond, we remain highly confident in Amneal’s outlook and the breadth and durability of the opportunities across our portfolio,” said Chirag and Chintu Patel, Co-Founders and Co-Chief Executive Officers of Amneal.

Second Quarter 2026 Results
Net revenue in the second quarter of 2026 was $796 million, an increase of 10% compared to $725 million in the second quarter of 2025. Specialty net revenue increased 17%, driven by key branded products, including CREXONT^®, BREKIYA^® autoinjector, and UNITHROID^®. Affordable Medicines net revenue increased 13%, driven by strong performance of our complex portfolio, including women’s health products, and new product launches. AvKARE net revenue decreased 4% due to a decline in the low margin distribution channel partially offset by growth in the government channel.

Net income attributable to Amneal Pharmaceuticals, Inc. was $58 million in the second quarter of 2026 compared to net income of $22 million in the second quarter of 2025, an increase of 157%, as higher revenue and gross profit, lower interest expense, and a lower tax provision more than offset increased SG&A expense.

Adjusted EBITDA in the second quarter of 2026 was $206 million, an increase of 12% compared to the second quarter of 2025, reflecting higher revenue and gross profit.

Diluted income per share in the second quarter of 2026 was $0.18 compared to diluted income per share of $0.07 for the second quarter of 2025, an increase of 157%, due to the aforementioned factors. Adjusted diluted earnings per share in the second quarter of 2026 was $0.30, an increase of 20% compared to $0.25 for the second quarter of 2025.

The Company presents GAAP and adjusted (non-GAAP) quarterly results. Please refer to the “Non-GAAP Financial Measures” section and the accompanying GAAP to non-GAAP reconciliation tables for more information.

Debt Repricing Further Reduces Future Interest Cost
In July 2026, the Company launched a repricing of its $2.084B Term Loan B, which will reduce the interest rate by 50 basis points from Secured Overnight Financing Rate (“SOFR”) plus 300 basis points to SOFR plus 250 basis points. The repricing is expected to close as early as August 3, 2026.

The Company also intends to obtain an additional $350 million Term Loan B financing to fund a portion of the purchase price of Kashiv Biosciences, as previously disclosed. Such additional Term Loans are expected to be incurred at the closing of the Kashiv acquisition at the reduced pricing. The repricing transaction is expected to generate about $12 million in annual cash interest savings and contribute towards the Company’s goal to reduce net leverage to below 3.0x by 2028.

Raising 2026 Full Year Guidance
We are raising select full year 2026 guidance metrics.

	Updated Guidance	Prior Guidance
Net revenue	$3.10 billion - $3.20 billion	$3.05 billion - $3.15 billion
Adjusted EBITDA (1)	$750 million - $780 million	$740 million - $770 million
Adjusted diluted EPS (2)	$0.96 - $1.06	$0.95 - $1.05
Operating cash flow (3)	$350 million - $400 million	$350 million - $400 million
Operating cash flow, excluding discrete items (4)	$375 million - $425 million	$375 million - $425 million
Capital expenditures (5)	~$150 million	~$110 million

(1)	Includes 100% of adjusted EBITDA from AvKARE. See also “Non-GAAP Financial Measures” below.
(2)	Accounts for 35% non-controlling interest in AvKARE. Assumes approximately 340 million weighted-average diluted shares outstanding for the year ending December 31, 2026.
(3)	Represents cash provided by operating activities.
(4)	Excludes discrete items such as opioid settlement costs of approximately $36 million and Kashiv acquisition and integration costs of approximately $30 million.
(5)	Reflects estimated capital expenditures and deposits for future acquisition of property, plant, and equipment.

Amneal’s 2026 estimates are based on management’s current expectations, including with respect to prescription trends, pricing levels, the timing of future product launches, the costs incurred and benefits realized of restructuring activities, and our long-term strategy. The Company’s financial statements are prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The Company cannot provide a reconciliation between non-GAAP projections and the most directly comparable measures in accordance with GAAP without unreasonable efforts because it is unable to predict with reasonable certainty the ultimate outcome of certain significant items required for the reconciliation. The items include, but are not limited to, acquisition-related expenses, restructuring expenses and benefits, asset impairments, legal settlements, and other gains and losses. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results.

Conference Call Information
Amneal will host a conference call and live webcast at 8:30 am Eastern Time today, July 30, 2026, to discuss its results. The live webcast and presentation will be accessible through the Investor Relations section of the Company’s website at https://investors.amneal.com. To access the call through a conference line, dial 1 (833) 461-5787 (in the U.S.) with access code 901153095. A replay of the conference call will be posted shortly after the call. For a list of toll-free international numbers, visit this website: https://help.events.q4inc.com/eahc/international-dial-in-numbers.

About Amneal
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX), headquartered in Bridgewater, New Jersey, is a diversified, global biopharmaceutical leader focused on expanding access to affordable and innovative medicines. Amneal was founded in 2002 by brothers and co-CEOs Chirag and Chintu Patel, and built on the belief that innovation only matters if it’s accessible. Today, Amneal has a diverse and growing portfolio of approximately 300 complex generic, specialty and biosimilar medicines, delivering more than 160 million prescriptions annually, primarily in the United States. Our Affordable Medicines segment spans retail generics, injectables, and biosimilars. Our Specialty segment provides branded treatments in neurology, including Parkinson’s disease and migraine, and endocrinology. Our AvKARE segment distributes pharmaceuticals and medical products to U.S. federal, retail, and institutional customers. For additional information, please visit amneal.com and follow us on LinkedIn.

Cautionary Statement on Forward-Looking Statements
Certain statements contained herein, regarding matters that are not historical facts, may be forward-looking statements (as defined in the U.S. Private Securities Litigation Reform Act of 1995). Such forward-looking statements include statements regarding management’s intentions, plans, beliefs, expectations, financial results, or forecasts for the future, including among other things: discussions of future operations; expected or estimated operating results and financial performance; statements regarding our positioning and potential growth, statements regarding our ability to create long-term value, and other non-historical statements. Words such as “plans,” “expects,” “will,” “anticipates,” “estimates,” and similar words, or the negatives thereof, are intended to identify estimates and forward-looking statements.

The reader is cautioned not to rely on these forward-looking statements. These forward-looking statements are based on current expectations of future events, including with respect to future market conditions, company performance and financial results, operational investments, business prospects, new strategies and growth initiatives, the competitive environment, and other events. If the underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Company.

Such risks and uncertainties include, but are not limited to: risks related to our proposed transaction to acquire membership interests of Kashiv BioSciences, LLC (“Kashiv”), our ability to successfully develop, license, acquire and commercialize new products on a timely basis; the competition we face in the pharmaceutical industry from brand and generic drug product companies, and the impact of that competition on our ability to set prices; our ability to obtain exclusive marketing rights for our products; the impact of illegal distribution and sale by third parties of counterfeit versions of our products or stolen products; the impact of negative market perceptions of us and the safety and quality of our products; our revenues are derived from the sales of a limited number of products, a substantial portion of which are through a limited number of customers; the continuing trend of consolidation of certain customer groups; the impact of supply chain disruption; the imposition of tariffs may adversely affect our business, results of operations and financial condition; a U.S. government shutdown could adversely impact our regulatory, operational and financial performance; legal, regulatory and legislative efforts by our brand competitors to deter competition from our generic alternatives; our dependence on information technology systems and infrastructure and the potential for cybersecurity incidents, and risks associated with artificial intelligence; the impact of a prolonged business interruption within our supply chain; our ability to attract, hire and retain highly skilled personnel; risks related to federal regulation of arrangements between manufacturers of branded and generic products; our reliance on certain licenses to proprietary technologies from time to time; the significant amount of resources we expend on research and development; the risk of claims brought against us by third parties; risks related to changes in the regulatory environment, including U.S. federal and state laws related to government contracting, healthcare fraud abuse and health information privacy and security and changes in such laws; changes to Food and Drug Administration product approval requirements and review processes; the impact of healthcare reform and changes in coverage and reimbursement levels and funding by governmental authorities and other third-party payers; our ability to identify, make and integrate acquisitions or investments in complementary businesses and products on advantageous terms; our dependence on third-party agreements for a portion of our product offerings; our potential expansion into additional international markets subjecting us to increased regulatory, economic, social and political uncertainties; the impact of global economic, political or other catastrophic events; our substantial amount of indebtedness and our ability to generate sufficient cash to service our indebtedness in the future, and the impact of interest rate fluctuations on such indebtedness; our obligations under a tax receivable agreement may be significant; and the high concentration of ownership of our Class A common stock by the Amneal Group. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company’s filings with the Securities and Exchange Commission, including under Item 1A, “Risk Factors” in the Company’s most recent Annual Report on Form 10-K and in its subsequent reports on Forms 10-Q and 8-K. Investors are cautioned not to place undue reliance on any such forward-looking statements, which speak only as of the date they are made. Forward-looking statements included herein speak only as of the date hereof and we undertake no obligation to revise or update such statements to reflect the occurrence of events or circumstances after the date hereof.

Non-GAAP Financial Measures
This release includes certain non-GAAP financial measures, including EBITDA, adjusted EBITDA, adjusted net income, adjusted diluted EPS, adjusted gross margin, adjusted operating income, net debt, gross leverage, and net leverage, which are intended as supplemental measures of the Company’s performance that are not required by or presented in accordance with GAAP.

Management uses these non-GAAP measures internally to evaluate and manage the Company’s operations and to better understand its business because they facilitate a comparative assessment of the Company’s operating performance relative to its performance based on results calculated under GAAP. These non-GAAP measures also isolate the effects of some items that vary from period to period without any correlation to core operating performance and eliminate certain charges that management believes do not reflect the Company’s operations and underlying operational performance. The compensation committee of the Company’s board of directors also uses certain of these measures to evaluate management’s performance and set its compensation. The Company believes that these non-GAAP measures also provide useful information to investors regarding certain financial and business trends relating to the Company’s financial condition and operating results facilitates an evaluation of the financial performance of the Company and its operations on a consistent basis. Providing this information therefore allows investors to make independent assessments of the Company’s financial performance, results of operations, cash flows, net leverage and trends while viewing the information through the eyes of management.

These non-GAAP measures are subject to limitations. The non-GAAP measures presented in this release may not be comparable to similarly titled measures used by other companies because other companies may not calculate one or more in the same manner. Additionally, the non-GAAP performance measures exclude significant expenses and income that are required by GAAP to be recorded in the Company’s financial statements; do not reflect changes in, or cash requirements for, working capital needs; and do not reflect interest expense, or the requirements necessary to service interest or principal payments on debt. Further, our historical adjusted results are not intended to project our adjusted results of operations or financial position for any future period. To compensate for these limitations, management presents and considers these non-GAAP measures in conjunction with the Company’s GAAP results; no non-GAAP measure should be considered in isolation from or as alternatives to any measure determined in accordance with GAAP. Readers should review the reconciliations included below, and should not rely on any single financial measure to evaluate the Company’s business.

A reconciliation of each historical non-GAAP measure to the most directly comparable GAAP measure is set forth below.

Contact
Anthony DiMeo
VP, Investor Relations
anthony.dimeo@amneal.com

Amneal Pharmaceuticals, Inc. Consolidated Statements of Operations (unaudited; in thousands, except per share amounts)
	Three Months Ended June 30,								Six Months Ended June 30,
	2026				2025				2026				2025
Net revenue	$	796,197			$	724,508			$	1,518,716			$	1,419,928
Cost of goods sold		461,689				438,255				864,095				877,784
Gross profit		334,508				286,253				654,621				542,144
Selling, general and administrative		148,722				124,266				287,582				242,554
Research and development		39,017				47,964				77,400				88,004
Intellectual property legal development expenses		2,087				2,017				3,629				3,784
Acquisition costs		7,600				—				12,753				—
Restructuring and other charges		554				1,024				1,204				1,595
Charges (credit) related to legal matters, net		8,057				(390	)			8,751				(390	)
Other operating income		(1,298	)			—				(8,239	)			(5,122	)
Operating income		129,769				111,372				271,541				211,719
Other (expense) income:
Interest expense, net		(55,043	)			(65,101	)			(108,404	)			(122,040	)
Foreign exchange (loss) gain, net		(1,950	)			8,256				(9,750	)			12,503
Loss on refinancing		—				—				(3,510	)			—
Increase in tax receivable agreement liability		(2,439	)			(4,420	)			(106	)			(15,107	)
Other income, net		653				1,604				1,395				2,122
Total other expense, net		(58,779	)			(59,661	)			(120,375	)			(122,522	)
Income before income taxes		70,990				51,711				151,166				89,197
Provision for income taxes		1,376				16,101				3,552				28,969
Net income		69,614				35,610				147,614				60,228
Less: Net income attributable to non-controlling interests		(11,952	)			(13,193	)			(27,696	)			(25,616	)
Net income attributable to Amneal Pharmaceuticals, Inc.	$	57,662			$	22,417			$	119,918			$	34,612
Net income per share attributable to Amneal Pharmaceuticals, Inc.’s Class A common stockholders:
Basic	$	0.18			$	0.07			$	0.38			$	0.11
Diluted	$	0.18			$	0.07			$	0.37			$	0.11
Weighted-average common shares outstanding:
Basic		319,200				313,739				317,620				312,404
Diluted		328,102				322,363				328,527				323,171

Amneal Pharmaceuticals, Inc. Condensed Consolidated Balance Sheets (unaudited; in thousands)
	June 30, 2026				December 31, 2025
Assets
Current assets:
Cash and cash equivalents	$	127,637			$	282,029
Restricted cash		8,643				28,842
Trade accounts receivable, net		1,020,360				895,143
Inventories		677,954				606,302
Prepaid expenses and other current assets		112,011				98,395
Related party receivables		424				470
Total current assets		1,947,029				1,911,181
Property, plant and equipment, net		456,877				442,950
Goodwill		593,499				595,470
Intangible assets, net		587,830				563,498
Operating lease right-of-use assets		44,361				38,832
Operating lease right-of-use assets - related party		13,723				15,216
Financing lease right-of-use assets		52,360				53,328
Other assets		80,669				57,805
Total assets	$	3,776,348			$	3,678,280
Liabilities and Stockholders’ Equity (Deficiency)
Current liabilities:
Accounts payable and accrued expenses	$	721,208			$	761,316
Current portion of liabilities for legal matters		18,488				43,256
Revolving credit facility		100,000				—
Current portion of long-term debt, net		5,961				6,761
Current portion of operating lease liabilities		9,040				8,668
Current portion of operating lease liabilities - related party		2,899				2,705
Current portion of financing lease liabilities		3,521				3,442
Related party payables - short term		22,070				55,485
Total current liabilities		883,187				881,633
Long-term debt, net		2,564,335				2,565,115
Operating lease liabilities		38,691				33,233
Operating lease liabilities - related party		12,712				14,195
Financing lease liabilities		54,602				54,927
Related party payables - long term		2,892				19,132
Liabilities for legal matters - long term		70,830				71,819
Other long-term liabilities		32,119				32,263
Total long-term liabilities		2,776,181				2,790,684
Redeemable non-controlling interests		83,956				77,292
Total stockholders’ equity (deficiency)		33,024				(71,329	)
Total liabilities and stockholders’ equity (deficiency)	$	3,776,348			$	3,678,280

Amneal Pharmaceuticals, Inc. Consolidated Statements of Cash Flows (unaudited; in thousands)
	Six Months Ended June 30,
	2026				2025
Cash flows from operating activities:
Net income	$	147,614			$	60,228
Adjustments to reconcile net income to net cash (used in) provided by operating activities:
Depreciation and amortization		90,991				120,272
Unrealized foreign currency loss (gain)		10,495				(11,813	)
Amortization of debt issuance costs and discount		7,954				13,686
Reclassification of cash flow hedge		5,788				(5,876	)
Loss on refinancing		3,510				—
Stock-based compensation		19,208				15,532
Inventory provision		44,957				38,432
Other operating charges and credits, net		3,086				2,254
Changes in assets and liabilities:
Trade accounts receivable, net		(125,765	)			(32,615	)
Inventories		(124,150	)			(36,039	)
Prepaid expenses, other current assets and other assets		(24,150	)			(10,015	)
Related party receivables		25				(1,108	)
Accounts payable, accrued expenses and other liabilities		(57,918	)			(67,004	)
Related party payables		(49,632	)			5,293
Net cash (used in) provided by operating activities		(47,987	)			91,227
Cash flows from investing activities:
Purchases of property, plant and equipment		(38,872	)			(35,992	)
Acquisition of intangible assets		(85,000	)			(5,100	)
Deposits for future acquisition of property, plant and equipment		(20,580	)			(4,632	)
Proceeds from sale of property, plant and equipment		—				1,379
Net cash used in investing activities		(144,452	)			(44,345	)
Cash flows from financing activities:
Payments of principal on debt, revolving credit facilities, financing leases and other		(147,027	)			(251,076	)
Proceeds from issuance of debt		134,673				—
Payments of deferred financing and refinancing costs		(1,982	)			(1,745	)
Borrowings on revolving credit facilities		100,000				218,000
Proceeds from exercise of stock options		80				754
Employee payroll tax withholding on restricted stock unit and performance stock unit vesting		(44,481	)			(21,828	)
Tax and other distributions to non-controlling interests		(21,067	)			(24,958	)
Proceeds from alliance party		510				—
Acquisition of non-controlling interest		(400	)			—
Net cash provided by (used in) financing activities		20,306				(80,853	)
Effect of foreign exchange rate on cash		(1,187	)			(777	)
Net decrease in cash, cash equivalents, and restricted cash		(173,320	)			(34,748	)
Cash, cash equivalents, and restricted cash - beginning of period		312,939				118,420
Cash, cash equivalents, and restricted cash - end of period	$	139,619			$	83,672
Cash and cash equivalents - end of period	$	127,637			$	71,544
Restricted cash - end of period		8,643				9,642
Long-term restricted cash included in other assets - end of period		3,339				2,486
Cash, cash equivalents, and restricted cash - end of period	$	139,619			$	83,672

Amneal Pharmaceuticals, Inc. Non-GAAP Reconciliations (unaudited, in thousands) Reconciliation of Net Income to EBITDA and Adjusted EBITDA
	Three Months Ended June 30,								Six Months Ended June 30,								Year Ended December 31,
	2026				2025				2026				2025				2025
Net income	$	69,614			$	35,610			$	147,614			$	60,228			$	127,933
Adjusted to add:
Interest expense, net		55,043				65,101				108,404				122,040				241,091
Provision for income taxes		1,376				16,101				3,552				28,969				11,276
Depreciation and amortization		47,800				60,113				90,991				120,272				223,572
EBITDA (Non-GAAP)	$	173,833			$	176,925			$	350,561			$	331,509			$	603,872
Adjusted to add (deduct):
Stock-based compensation expense		10,392				8,274				19,208				15,402				31,823
Acquisition, site closure, and idle facility expenses (1)		8,076				1,203				13,758				2,444				5,301
Restructuring and other charges		—				1,024				499				1,595				4,208
Loss on refinancing (2)		—				—				3,510				—				31,365
Charges (credit) related to legal matters, net (3)		8,057				(390	)			8,751				(390	)			(390	)
Asset impairment charges (4)		—				36				—				104				23,022
Foreign exchange loss (gain)		1,950				(8,256	)			9,750				(12,503	)			(7,635	)
Increase in tax receivable agreement liability		2,439				4,420				106				15,107				6,588
Other (5)		1,703				424				2,317				370				(9,739	)
Adjusted EBITDA (Non-GAAP)	$	206,450			$	183,660			$	408,460			$	353,638			$	688,415

Amneal Pharmaceuticals, Inc. Non-GAAP Reconciliations (unaudited, $ in thousands) Calculation of Net Debt and Net Leverage
	June 30, 2026				December 31, 2025
Term Loan Due 2032	$	2,084,263			$	2,094,750
Senior Notes Due 2032		600,000				600,000
2025 Revolving Credit Facility		100,000				—
Gross debt (6)	$	2,784,263			$	2,694,750
Less: Cash and cash equivalents		127,637				282,029
Net debt (Non-GAAP) (7)	$	2,656,626			$	2,412,721
	Adjusted EBITDA (Non-GAAP)				Adjusted EBITDA (Non-GAAP)
Year ended December 31, 2025	$	688,415			$	688,415
Less: Six months ended June 30, 2025		353,638
Add: Six months ended June 30, 2026		408,460
Last twelve months ended June 30, 2026	$	743,237
	Last Twelve Months Ended June 30, 2026				Year Ended December 31, 2025
Gross leverage (Non-GAAP) (8)	3.7x				3.9x
Net leverage (Non-GAAP) (9)	3.6x				3.5x

Amneal Pharmaceuticals, Inc. Non-GAAP Reconciliations (unaudited; in thousands, except per share amounts) Reconciliation of Net Income to Adjusted Net Income and Calculation of Adjusted Diluted Earnings Per Share
	Three Months Ended June 30,								Six Months Ended June 30,
	2026				2025				2026				2025
Net income	$	69,614			$	35,610			$	147,614			$	60,228
Adjusted to add (deduct):
Non-cash interest		6,944				7,411				13,681				7,745
GAAP provision for income taxes		1,376				16,101				3,552				28,969
Amortization		34,004				44,820				63,025				89,094
Stock-based compensation expense		10,392				8,274				19,208				15,402
Acquisition, site closure, and idle facility expenses (1)		8,076				1,189				13,758				2,416
Restructuring and other charges		—				1,017				499				1,588
Loss on refinancing		—				—				3,510				—
Charges (credit) related to legal matters, including interest, net (3)		9,117				(390	)			10,567				(390	)
Asset impairment charges		—				36				—				104
Increase in tax receivable agreement liability		2,439				4,420				106				15,107
Other		1,703				424				2,317				380
Provision for income taxes (10)		(33,005	)			(26,089	)			(61,760	)			(48,854	)
Net income attributable to non-controlling interests		(11,952	)			(13,193	)			(27,696	)			(25,616	)
Adjusted net income (Non-GAAP)	$	98,708			$	79,630			$	188,381			$	146,173
Weighted average diluted shares outstanding (11)		328,102				322,363				328,527				323,171
Diluted earnings per share (GAAP)	$	0.18			$	0.07			$	0.37			$	0.11
Adjusted diluted earnings per share (Non-GAAP)	$	0.30			$	0.25			$	0.57			$	0.45

Amneal Pharmaceuticals, Inc. Non-GAAP Reconciliations (unaudited) Explanations for Non-GAAP Reconciliations
(1)	Acquisition, site closure, and idle facility expenses for the three and six months ended June 30, 2026 primarily included acquisition costs associated with the announced agreement to acquire Kashiv BioSciences, LLC and rent for vacated properties. Acquisition, site closure, and idle facility expenses for the three and six months ended June 30, 2025 and year ended December 31, 2025 primarily included costs related to a planned facility closure and rent for vacated properties.
(2)	For the year ended December 31, 2025, loss on refinancing was primarily comprised of debt issuance costs associated with the portion of the Term Loan Due 2028 that was modified as part of the Company’s debt refinancing on August 1, 2025. Refer to Note 14. Debt in the Company’s 2025 Annual Report on Form 10-K for information about the Company’s debt as of December 31, 2025.
(3)	For the three months ended June 30, 2026, charges related to legal matters, net were $8.1 million, primarily consisting of charges related to antitrust class action litigation. For the six months ended June 30, 2026, charges related to legal matters, net were $8.8 million, primarily consisting of (i) a $21.2 million charge associated with certain states electing a 25% cash conversion in lieu of product under the Nationwide Opioids Settlement Agreement, partially offset by a $20.8 million discount recorded on the expected settlement payments as of the agreement’s effective date and (ii) charges associated with antitrust class action litigation. For the three and six months ended June 30, 2026, charges related to legal matters, including interest, net also included interest expense associated with the Nationwide Opioids Settlement Agreement. For additional information regarding the Nationwide Opioids Settlement Agreement and antitrust class action litigation, refer to Note 16. Commitments and Contingencies in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.
(4)	For the year ended December 31, 2025, asset impairment charges were primarily related to a Specialty segment product right for which the Company significantly reduced the cash flow forecast after receipt of a complete response letter dated July 22, 2025 from the U.S. Food and Drug Administration regarding a supplemental new drug application.
(5)	For the year ended December 31, 2025, the caption “other” primarily reflects a non-recurring, non-operating, non-cash gain.
(6)	Refer to Note 14. Debt in the Company’s 2025 Annual Report on Form 10-K for additional information.
(7)	Net debt was calculated as the total outstanding principal on the Company’s debt less cash and cash equivalents.
(8)	Gross leverage was calculated by dividing gross debt as of June 30, 2026 and December 31, 2025 by adjusted EBITDA for the last twelve months ended June 30, 2026 and year ended December 31, 2025, respectively.
(9)	Net leverage was calculated by dividing net debt as of June 30, 2026 and December 31, 2025 by adjusted EBITDA for the last twelve months ended June 30, 2026 and year ended December 31, 2025, respectively.
(10)	The non-GAAP effective tax rates for the three and six months ended June 30, 2026 were 25.1% and 24.7%, respectively. The non-GAAP effective tax rates for the three and six months ended June 30, 2025 were 24.7% and 25.0%, respectively.
(11)	Weighted average diluted shares outstanding for the three and six months ended June 30, 2026 and 2025 consisted of fully diluted Class A common stock (inclusive of the effect of dilutive securities).

Amneal Pharmaceuticals, Inc. Non-GAAP Reconciliations (unaudited, $ in thousands) Reconciliation of Consolidated GAAP to Non-GAAP Operating Results
	Three Months Ended June 30, 2026												Three Months Ended June 30, 2025
	As Reported				Adjustments				Non-GAAP				As Reported				Adjustments				Non-GAAP
Net revenue	$	796,197			$	—			$	796,197			$	724,508			$	—			$	724,508
Cost of goods sold (1)		461,689				(33,317	)			428,372				438,255				(44,050	)			394,205
Gross profit		334,508				33,317				367,825				286,253				44,050				330,303
Gross margin %		42.0	%							46.2	%			39.5	%							45.6	%
Selling, general and administrative (2)		148,722				(13,781	)			134,941				124,266				(11,424	)			112,842
Research and development (3)		39,017				(855	)			38,162				47,964				(1,573	)			46,391
Intellectual property legal development expenses		2,087				—				2,087				2,017				—				2,017
Acquisition costs (4)		7,600				(7,600	)			—				—				—				—
Restructuring and other charges		554				—				554				1,024				(1,024	)			—
Charges (credits) related to legal matters, net (5)		8,057				(8,057	)			—				(390	)			390				—
Other operating income		(1,298	)			—				(1,298	)			—				—				—
Operating income	$	129,769			$	63,610			$	193,379			$	111,372			$	57,681			$	169,053

(1)	Adjustments for the three months ended June 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($1.0 million in each period) and amortization expense ($32.3 million and $43.1 million).
(2)	Adjustments for the three months ended June 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($8.6 million and $6.4 million), amortization expense ($2.6 million and $2.7 million), site closure costs ($0.5 million in each period), and other ($2.1 million and $1.8 million).
(3)	Adjustments for the three months ended June 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($0.9 million in each period) and site closure costs (none and $0.7 million).
(4)	Acquisition costs for the three months ended June 30, 2026 included acquisition costs associated with the announced agreement to acquire Kashiv BioSciences, LLC.
(5)	For the three months ended June 30, 2026, charges related to legal matters, net were $8.1 million, primarily consisting of charges related to antitrust class action litigation. For additional information regarding antitrust class action litigation, refer to Note 16. Commitments and Contingencies in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.

Amneal Pharmaceuticals, Inc. Non-GAAP Reconciliations (unaudited, $ in thousands) Reconciliation of Consolidated GAAP to Non-GAAP Operating Results
	Six Months Ended June 30, 2026												Six Months Ended June 30, 2025
	As Reported				Adjustments				Non-GAAP				As Reported				Adjustments				Non-GAAP
Net revenue	$	1,518,716			$	—			$	1,518,716			$	1,419,928			$	—			$	1,419,928
Cost of goods sold (1)		864,095				(61,628	)			802,467				877,784				(87,565	)			790,219
Gross profit		654,621				61,628				716,249				542,144				87,565				629,709
Gross margin %		43.1	%							47.2	%			38.2	%							44.3	%
Selling, general and administrative (2)		287,582				(25,062	)			262,520				242,554				(20,971	)			221,583
Research and development (3)		77,400				(1,628	)			75,772				88,004				(3,053	)			84,951
Intellectual property legal development expenses		3,629				—				3,629				3,784				—				3,784
Acquisition costs (4)		12,753				(12,753	)			—				—				—				—
Restructuring and other charges		1,204				(499	)			705				1,595				(1,595	)			—
Charges (credits) related to legal matters, net (5)		8,751				(8,751	)			—				(390	)			390				—
Other operating income		(8,239	)			—				(8,239	)			(5,122	)			—				(5,122	)
Operating income	$	271,541			$	110,321			$	381,862			$	211,719			$	112,794			$	324,513

(1)	Adjustments for the six months ended June 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($2.0 million and $1.9 million), amortization expense ($59.6 million and $85.6 million), and asset impairment charges (none and $0.1 million).
(2)	Adjustments for the six months ended June 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($15.6 million and $11.9 million), amortization expense ($5.3 million and $5.4 million), site closure costs ($1.0 million in each period), and other ($3.2 million and $2.6 million).
(3)	Adjustments for the six months ended June 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($1.6 million and $1.7 million) and site closure costs (none and $1.4 million).
(4)	Acquisition costs for the six months ended June 30, 2026 included acquisition costs associated with the announced agreement to acquire Kashiv BioSciences, LLC.
(5)	For the six months ended June 30, 2026, charges related to legal matters, net were $8.8 million, primarily consisting of (i) a $21.2 million charge associated with certain states electing a 25% cash conversion in lieu of product under the Nationwide Opioids Settlement Agreement, partially offset by a $20.8 million discount recorded on the expected settlement payments as of the agreement’s effective date and (ii) charges associated with antitrust class action litigation. For additional information regarding the Nationwide Opioids Settlement Agreement and antitrust class action litigation, refer to Note 16. Commitments and Contingencies in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.

Amneal Pharmaceuticals, Inc. Affordable Medicines Segment Reconciliation of GAAP to Non-GAAP Operating Results (1) (unaudited; $ in thousands)
	Three Months Ended June 30, 2026												Three Months Ended June 30, 2025
	As Reported				Adjustments				Non-GAAP				As Reported				Adjustments				Non-GAAP
Net revenue	$	489,913			$	—			$	489,913			$	433,425			$	—			$	433,425
Cost of goods sold (2)		282,684				(14,513	)			268,171				252,646				(11,171	)			241,475
Gross profit		207,229				14,513				221,742				180,779				11,171				191,950
Gross margin %		42.3	%							45.3	%			41.7	%							44.3	%
Selling, general and administrative (3)		42,367				(2,939	)			39,428				34,226				(2,183	)			32,043
Research and development (4)		33,023				(725	)			32,298				41,899				(777	)			41,122
Intellectual property legal development expenses		2,002				—				2,002				1,978				—				1,978
Restructuring and other charges		—				—				—				683				(683	)			—
Charges (credits) related to legal matters, net (5)		8,057				(8,057	)			—				(390	)			390				—
Other operating income		(1,298	)			—				(1,298	)			—				—				—
Operating income	$	123,078			$	26,234			$	149,312			$	102,383			$	14,424			$	116,807

(1)	Revenue, cost of goods sold, and gross profit from the sale of Amneal products by AvKARE were included in our Affordable Medicines segment.
(2)	Adjustments for the three months ended June 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($1.0 million and $0.9 million) and amortization expense ($13.5 million and $10.3 million).
(3)	Adjustments for the three months ended June 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($2.5 million and $1.6 million) and site closure costs ($0.5 million and $0.6 million).
(4)	Adjustments for the three months ended June 30, 2026 and 2025 were comprised of stock-based compensation expense.
(5)	For the three months ended June 30, 2026, charges related to legal matters, net were $8.1 million, primarily consisting of charges related to antitrust class action litigation. For additional information regarding antitrust class action litigation, refer to Note 16. Commitments and Contingencies in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.

Amneal Pharmaceuticals, Inc. Affordable Medicines Segment Reconciliation of GAAP to Non-GAAP Operating Results (1) (unaudited; $ in thousands)
	Six Months Ended June 30, 2026												Six Months Ended June 30, 2025
	As Reported				Adjustments				Non-GAAP				As Reported				Adjustments				Non-GAAP
Net revenue	$	913,150			$	—			$	913,150			$	848,133			$	—			$	848,133
Cost of goods sold (2)		515,128				(24,083	)			491,045				495,279				(22,046	)			473,233
Gross profit		398,022				24,083				422,105				352,854				22,046				374,900
Gross margin %		43.6	%							46.2	%			41.6	%							44.2	%
Selling, general and administrative (3)		83,685				(5,371	)			78,314				67,941				(3,999	)			63,942
Research and development (4)		66,309				(1,402	)			64,907				72,879				(1,466	)			71,413
Intellectual property legal development expenses		3,495				—				3,495				3,691				—				3,691
Restructuring and other charges		—				—				—				683				(683	)			—
Charges (credits) related to legal matters, net (5)		8,751				(8,751	)			—				(390	)			390				—
Other operating income		(8,239	)			—				(8,239	)			(5,122	)			—				(5,122	)
Operating income	$	244,021			$	39,607			$	283,628			$	213,172			$	27,804			$	240,976

(1)	Revenue, cost of goods sold, and gross profit from the sale of Amneal products by AvKARE were included in our Affordable Medicines segment.
(2)	Adjustments for the six months ended June 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($2.0 million and $1.8 million), amortization expense ($22.1 million and $20.1 million), and asset impairment charges (none and $0.1 million).
(3)	Adjustments for the six months ended June 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($4.4 million and $2.9 million) and site closure costs ($1.0 million and $1.1 million).
(4)	Adjustments for the six months ended June 30, 2026 and 2025 were comprised of stock-based compensation expense.
(5)	For the six months ended June 30, 2026, charges related to legal matters, net were $8.8 million, primarily consisting of (i) a $21.2 million charge associated with certain states electing a 25% cash conversion in lieu of product under the Nationwide Opioids Settlement Agreement, partially offset by a $20.8 million discount recorded on the expected settlement payments as of the agreement’s effective date and (ii) charges associated with antitrust class action litigation. For additional information regarding the Nationwide Opioids Settlement Agreement and antitrust class action litigation, refer to Note 16. Commitments and Contingencies in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.

Amneal Pharmaceuticals, Inc. Specialty Segment Reconciliation of GAAP to Non-GAAP Operating Results (unaudited; $ in thousands)
	Three Months Ended June 30, 2026												Three Months Ended June 30, 2025
	As Reported				Adjustments				Non-GAAP				As Reported				Adjustments				Non-GAAP
Net revenue	$	149,295			$	—			$	149,295			$	128,043			$	—			$	128,043
Cost of goods sold (1)		48,265				(18,804	)			29,461				55,795				(32,880	)			22,915
Gross profit		101,030				18,804				119,834				72,248				32,880				105,128
Gross margin %		67.7	%							80.3	%			56.4	%							82.1	%
Selling, general and administrative (2)		40,095				(664	)			39,431				30,314				(486	)			29,828
Research and development (3)		5,994				(130	)			5,864				6,065				(796	)			5,269
Intellectual property legal development expenses		85				—				85				39				—				39
Restructuring and other charges		—				—				—				341				(341	)			—
Operating income	$	54,856			$	19,598			$	74,454			$	35,489			$	34,503			$	69,992

(1)	Adjustments for the three months ended June 30, 2026 and 2025 were comprised of amortization expense.
(2)	Adjustments for the three months ended June 30, 2026 and 2025 were comprised of stock-based compensation expense.
(3)	Adjustments for the three months ended June 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($0.1 million in each period) and site closure costs (none and $0.7 million).

Amneal Pharmaceuticals, Inc. Specialty Segment Reconciliation of GAAP to Non-GAAP Operating Results (unaudited; $ in thousands)
	Six Months Ended June 30, 2026												Six Months Ended June 30, 2025
	As Reported				Adjustments				Non-GAAP				As Reported				Adjustments				Non-GAAP
Net revenue	$	282,560			$	—			$	282,560			$	236,340			$	—			$	236,340
Cost of goods sold (1)		91,285				(37,545	)			53,740				108,878				(65,520	)			43,358
Gross profit		191,275				37,545				228,820				127,462				65,520				192,982
Gross margin %		67.7	%							81.0	%			53.9	%							81.7	%
Selling, general and administrative (2)		74,786				(1,190	)			73,596				61,292				(831	)			60,461
Research and development (3)		11,091				(225	)			10,866				15,125				(1,587	)			13,538
Intellectual property legal development expenses		134				—				134				93				—				93
Restructuring and other charges		347				(347	)			—				471				(471	)			—
Operating income	$	104,917			$	39,307			$	144,224			$	50,481			$	68,409			$	118,890

(1)	Adjustments for the six months ended June 30, 2026 and 2025 were comprised of amortization expense.
(2)	Adjustments for the six months ended June 30, 2026 and 2025 were comprised of stock-based compensation expense.
(3)	Adjustments for the six months ended June 30, 2026 and 2025, respectively, were comprised of stock-based compensation expense ($0.2 million in each period) and site closure costs (none and $1.4 million).

Amneal Pharmaceuticals, Inc. AvKARE Segment Reconciliation of GAAP to Non-GAAP Operating Results (1) (unaudited; $ in thousands)
	Three Months Ended June 30, 2026												Three Months Ended June 30, 2025
	As Reported				Adjustments				Non-GAAP				As Reported				Adjustments				Non-GAAP
Net revenue	$	156,989			$	—			$	156,989			$	163,040			$	—			$	163,040
Cost of goods sold		130,740				—				130,740				129,814				—				129,814
Gross profit		26,249				—				26,249				33,226				—				33,226
Gross margin %		16.7	%							16.7	%			20.4	%							20.4	%
Selling, general and administrative (2)		16,913				(2,648	)			14,265				15,079				(2,700	)			12,379
Operating income	$	9,336			$	2,648			$	11,984			$	18,147			$	2,700			$	20,847

(1)	Revenue, cost of goods sold, and gross profit from the sale of Amneal products by AvKARE were included in our Affordable Medicines segment.
(2)	Adjustments for the three months ended June 30, 2026 and 2025 were comprised of amortization expense.

Amneal Pharmaceuticals, Inc. AvKARE Segment Reconciliation of GAAP to Non-GAAP Operating Results (1) (unaudited; $ in thousands)
	Six Months Ended June 30, 2026												Six Months Ended June 30, 2025
	As Reported				Adjustments				Non-GAAP				As Reported				Adjustments				Non-GAAP
Net revenue	$	323,006			$	—			$	323,006			$	335,455			$	—			$	335,455
Cost of goods sold		257,682				—				257,682				273,627				—				273,627
Gross profit		65,324				—				65,324				61,828				—				61,828
Gross margin %		20.2	%							20.2	%			18.4	%							18.4	%
Selling, general and administrative (2)		33,593				(5,296	)			28,297				30,773				(5,400	)			25,373
Operating income	$	31,731			$	5,296			$	37,027			$	31,055			$	5,400			$	36,455

(1)	Revenue, cost of goods sold, and gross profit from the sale of Amneal products by AvKARE were included in our Affordable Medicines segment.
(2)	Adjustments for the six months ended June 30, 2026 and 2025 were comprised of amortization expense.

FAQ

How did Amneal (AMRX) perform in Q2 2026 by revenue and earnings?

Amneal reported Q2 2026 net revenue of $796 million and GAAP net income of $58 million. According to Amneal, this represented 10% revenue growth and a 157% increase in net income year over year, with adjusted EBITDA of $206 million and adjusted diluted EPS of $0.30.

What 2026 guidance did Amneal (AMRX) raise with its Q2 2026 results?

Amneal raised 2026 guidance for net revenue to $3.10–$3.20 billion, adjusted EBITDA to $750–$780 million, and adjusted diluted EPS to $0.96–$1.06. According to Amneal, operating cash flow guidance remains $350–$400 million, with capital expenditures now expected at about $150 million.

What is Amneal’s Term Loan B repricing announced around Q2 2026 earnings?

Amneal launched a repricing of its $2.084 billion Term Loan B, reducing the rate from SOFR+300 bps to SOFR+250 bps. According to Amneal, this repricing is expected to close as early as August 3, 2026 and generate about $12 million in annual cash interest savings.

How will Amneal (AMRX) finance the pending Kashiv Biosciences acquisition?

Amneal intends to obtain an additional $350 million Term Loan B to fund a portion of the Kashiv Biosciences purchase price. According to Amneal, these additional term loans are expected to be incurred at the closing of the Kashiv acquisition, using the reduced pricing from the recent repricing.

How did Amneal’s business segments perform in Q2 2026?

In Q2 2026, Specialty net revenue increased 17% and Affordable Medicines net revenue increased 13%, while AvKARE net revenue declined 4%. According to Amneal, growth was driven by key branded products and complex generics, partly offset by lower revenue in AvKARE’s low-margin distribution channel.

What were Amneal’s cash flow and balance sheet trends in the first half of 2026?

For the six months ended June 30, 2026, net cash used in operating activities was $47.987 million and net cash used in investing was $144.452 million. According to Amneal, cash and cash equivalents ended the period at $127.637 million, with total stockholders’ equity at $33.024 million.